Gothenburg, Sweden (PR NEWSWIRE) May 6, 2021  Glooko Inc., a leading provider of remote patient monitoring and data management solutions for diabetes and other chronic conditions, today announced a strategic collaboration with Eli Lilly and Company for people with diabetes that use Lilly’s connected insulin pen solutions.  The technology collaboration will ease insulin management for people with diabetes and their healthcare providers in markets outside the U.S., via integration of Lilly’s Tempo Pen™ and Tempo Smart Button™ (currently in late-stage development) with Glooko’s platform.

Glooko’s platforms are compatible with over 95 percent of diabetes devices globally, and the Lilly collaboration expands upon the Company’s device-agnostic model for remote patient monitoring and patient data management. This gives patients and their healthcare providers more freedom of choice for managing their care.

The Tempo Pen is an enhanced version of Lilly’s current prefilled, disposable insulin pen to which the Tempo Smart Button (pending CE mark) attaches. Through this new agreement, the Tempo Smart Button will pair with Glooko’s software to facilitate the integration of personalized healthcare data from the Tempo Pen, allowing it to be viewed and analyzed alongside other relevant data from other devices, fitness trackers and food logs. The integrated and actionable insights available in Glooko will improve the standard of diabetes care.

“Lilly is a valued partner for Glooko, and we are pleased to collaborate with them on this important digital health launch,” said Russ Johannesson, CEO of Glooko. “Studies have shown that when smart insulin devices are synced with digital health tools, it improves outcomes for people living with diabetes. We are excited about continuing to expand the availability of our solution and look forward to helping more people manage their diabetes through our innovative products.”

Lilly aims to receive CE mark for the Tempo Smart Button later in 2021 and will launch the Tempo Pen and Tempo Smart Button with Glooko’s platform following this certification.

“We’re pleased to work alongside Glooko on our commitment to improving diabetes outcomes by bringing together medicine and digital solutions for the global diabetes community,” said Marie Schiller, Vice President of Product Development for Connected Care and Insulins at Lilly. “Insulin dose logging is often an incomplete piece of the diabetes management puzzle for people who use insulin pens and manually track their doses. By integrating data from the connected insulin pen solutions into globally-used compatible software, we aim to support improved decision-making for people with diabetes and their healthcare providers with accurate, real-time data collection.”

Glooko is the global leader in diabetes patient data with over 32 billion data points. Adding Lilly’s connected insulin pens in additional global markets will increase this data at Glooko, and benefit healthcare providers and clinical researchers around the world, via access to real world data and applying it to studies for improved therapeutics for patients with chronic conditions.

About Diabetes
An estimated 463 million adults worldwide⁽¹⁾ have diabetes. Type 2 diabetes is the most common type, accounting for an estimated 90 to 95 percent of all diabetes cases.⁽²⁾

About Eli Lilly and Company 
Lilly is a global health care leader that unites caring with discovery to create medicines that make life better for people around the world. We were founded more than a century ago by a man committed to creating high-quality medicines that meet real needs, and today we remain true to that mission in all our work. Across the globe, Lilly employees work to discover and bring life-changing medicines to those who need them, improve the understanding and management of disease, and give back to communities through philanthropy and volunteerism. To learn more about Lilly, please visit us at lilly.com and lilly.com/newsroom.

About Glooko
glooko.com.

Contacts:
Media, North America
Tanya Rodante
Director of Communication, Glooko
[email protected]

Media Europe
Anders Sonesson
General manager EMEA/APAC, Glooko
[email protected]
+46735458888

_________

(1) International Diabetes Federation. IDF Diabetes Atlas, 9thedn. Brussels, Belgium: International Diabetes Federation, 2019. Available at:http://diabetesatlas.org.

(2) Centers for Disease Control and Prevention. National Diabetes Statistics Report, 2020. Atlanta, GA: Centers for Disease Control and Prevention, U.S. Dept. of Health and Human Services; 2020.

New Capital Reflects the Company’s Increasing Trajectory and Market Growth

PALO ALTO, CA, March 16, 2021 /PRNewswire/- Glooko Inc., a leading provider of remote patient monitoring and chronic care management solutions including diabetes and obesity has raised a $30 million Series D round of funding. The financing was led by Health Catalyst Capital along with participation from existing investors Canaan Partners, Georgian, Novo Nordisk, Insulet and Mayo Clinic. Proceeds will be used to accelerate organic growth and strategic initiatives across the company’s broad and growing product line of advanced digital health solutions.

“Glooko has done a remarkable job of bringing to market cutting edge digital healthcare platforms, which empower people with diabetes to better manage their disease and improve their lives. This technology enables physicians to take better care of patients with diabetes by strengthening the engagement between people with diabetes and their healthcare providers,” said Charles Boorady, Founder & Managing Partner of Health Catalyst Capital. “As a result of Glooko’s innovations, the company has experienced rapid market adoption growing its global ecosystem to more than 7,500 clinics and has entered into partnerships with many of the world’s largest diabetes medical device companies and pharmaceutical companies as well as top healthcare systems. We look forward to supporting the company in its next phase of growth as it invests in new capabilities supporting the management of chronic care and serving even more stakeholders.”

This round of financing follows a successful 2020 for Glooko, the most successful in its history despite the global pandemic. Last year, the Company’s growth included key partnerships with major healthcare systems and extended long-term existing partnerships with several global diabetes industry leading companies such as Insulet and Novo Nordisk.

The new proceeds will accelerate execution of Glooko’s commercial strategy, including increasing adoption of Glooko’s remote patient monitoring platform, widening commercialization of products in clinical research and expanding into additional therapy areas.

This is an unprecedented time in healthcare and technology. The demand for our platform demonstrates this sea-change. Glooko has experienced considerable growth, and this funding allows us to build on our strong momentum in providing the advanced technologies we’re known for,” said Russ Johannesson, CEO of Glooko. “Now more than ever, the healthcare industry is seeking new and smarter technologies, whether it’s for patient care or researching new therapies. I am excited to lead the team at Glooko in our mission to improve health outcomes by connecting people with diabetes and other chronic conditions with their healthcare professionals.”

About Glooko
Glooko is transforming digital health by connecting people with diabetes and their healthcare professionals, enabling telehealth, clinical research, and improved collaboration. The company’s software platforms empower diabetes management by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, pens, and activity trackers – bringing insights together in one place. Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with the vast majority of diabetes devices available, giving people with diabetes and their care teams the freedom of choice. Over 3 million users have benefited from diabetes data insights using Glooko’s solutions, which are trusted by world leaders in diabetes care, and used in 27 countries across 20 languages. Their US headquarters are located in Palo Alto, CA with European headquarters in Gothenburg, Sweden. Learn more at glooko.com

About Health Catalyst Capital
Health Catalyst Capital Management is an independent fund manager investing in private, growth-stage healthcare information technology and technology-enabled services businesses that seek to improve the human condition and promote value-based care.
HCC was formed by a team of experienced healthcare investors and operators seeking profitable investment opportunities, while at the same time seeking to improve the human condition and promote value-based care.Learn more at healthcatalystcapital.com

Investors
Steve Lien
Chief Financial Officer, Glooko
+1650-720-5310

Media, North America
Tanya Rodante
Director of Communication, Glooko
[email protected]

Media, Europe
Anders Sonesson
General Manager EMEA/APAC, Glooko
[email protected]
+46735458888

New education platform focuses on diabetes technology training, data management and remote patient monitoring (RPM)

Gothenburg, Sweden (PR NEWSWIRE) — October 28, 2020 — Glooko AB (“Glooko” or “The Company”) today announced, in partnership with the Diabetes Technology Network (DTN)/ Association of British Clinical Diabetologists (ABCD), a new online medical education programme for clinicians who treat people with diabetes in the UK. The programme will help clinicians keep their knowledge base current on the ever-growing assortment of new diabetes technologies that manufacturers make available to people with diabetes. It was inspired after discussions with the National Health Service England (NHSE), as part of its effort to ensure that all healthcare professionals learn uniformly about technology.

Currently, the number of people diagnosed with diabetes in the UK is estimated to be 3.5 million and expected to rise to 5 million by 2025.¹

For people with diabetes and their healthcare providers, managing the myriad technologies like glucose monitors and insulin pumps, and the data volume that accompany these technologies, is a well-established challenge. And while tech-based services like web-based programs, telehealth, mobile apps and remote monitoring are improving users’ accessibility and connectivity, the adoption of these innovations has been slow.²

The Academy™ education programme focuses exclusively on diabetes health tech, and includes an extensive range of online courses for healthcare professionals (HCPs), with the intent to increase knowledge, training and usage of these devices – ultimately improving outcomes. All courses are accessed as video modules through the diasend® diabetes data management app and portal, via the DigiBete Global platform.

The programme is available to all diabetes healthcare professionals in the UK at no cost, and is funded in part via sponsorships from global industry partners like Abbott, AgaMatrix, Dexcom, Insulet, Medtronic and Roche Diabetes Care.

Another goal of the educational platform is to reduce barriers to the adoption of diabetes digital tools. DTN UK/ABCD provides guidance on educational content and ensures that the programme aligns with current and future National Health Service England (NHSE) policy/pathways. Healthcare professionals earn CPD accreditation for completing the programme.

“Academy™ is an important investment that sets a new standard for professional development in the diabetes medical technology industry,” said Russ Johannesson, Chief Executive Officer of Glooko. “In collaboration with the NHSE and DTN UK/ABCD, we’ve developed a new, extensive curriculum that will not only equip HCPs to access training that is relevant to their technology skills development, but it will also build a wider range of their capabilities as we move increasingly towards a remote patient monitoring (RPM) environment.”

The curriculum covers over 95% of the diabetes device manufacturers and their technologies, and HCPs that complete the programme will receive Continuing Professional Development accreditation as well as DTN UK/ABCD certification.

“As diabetes technology becomes increasingly widespread in routine clinical practice, we need to train all levels of our diabetes and wider health workforce in what these technologies are and how to use the large amounts of data they generate,” Professor Pratik Choudhary, Professor / Honorary Consultant in Diabetes and Chair of DTN UK, said. “Use of these technologies has transformed how we deliver care, especially during these challenging times. We firmly believe that the collective efforts that we’re cultivating with world-class digital health companies like Glooko will create more value and positively impact outcomes that matter to people with diabetes.”

Prof. Partha Kar, National Specialty Advisor of Diabetes at NHS England, stated “As Nick Fury once said in The Avengers ‘There was an idea’. It’s been a pleasure to bring together multiple partners across industry, specialists in diabetes care – facilitated by Glooko for this project. As diabetes technologies continually advance and improve, it’s critical that healthcare providers have access to the most exceptional training on the plethora of devices that people with diabetes use on a daily basis. This platform will hopefully go a long way in ensuring education is available uniformly across the NHS – and thereby improving access and outcomes for those living with diabetes.”

Glooko is committed to incorporating newly-developed, online immersive education experiences that complement Glooko’s portfolio of industry-leading diabetes digital health solutions.

The Academy™ programme is part of Glooko’s global mission to improve health outcomes by connecting people with diabetes and their healthcare professionals, enabling telehealth, clinical research and improved collaboration.

Rollout of the programme will begin in November 2020 to coincide with World Diabetes Day.

For more information about Academy™: get.glooko.com/academy.

ABOUT GLOOKO
Glooko is transforming digital health by connecting people with diabetes and their health care professionals, enabling telehealth, clinical research, and improved collaboration.
The company’s software platforms, Glooko and diasend®, empower diabetes management by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, pens, and activity trackers – bringing insights together in one place. Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with the vast majority of diabetes devices available, giving people with diabetes and their care teams the freedom of choice. 2.8 million users have benefited from diabetes data insights using Glooko’s solutions, which are trusted by world leaders in diabetes care, and used in 26 countries across 15 languages. Learn more at glooko.com.

Sources:
1. Diabetes Facts and Stats: 2015 – Diabetes UK, 2015
2. Diabetes Self-management Education and Support in Adults With Type 2 Diabetes: A Consensus Report of the American Diabetes Association, the Association of Diabetes Care and Education Specialists, the Academy of Nutrition and Dietetics, the American Academy of Family Physicians, the American Academy of PAs, the American Association of Nurse Practitioners, and the American Pharmacists Association Diabetes Care / American Diabetes Association (ADA) – June 8, 2020

Media Contacts:
Glooko Inc: [email protected]

MOUNTAIN VIEW, Calif, Aug 12, 2020 – As Glooko continues its journey to transform digital health by connecting people with diabetes and their health care professionals, enabling telehealth, clinical research, and improved collaboration, today they announced the addition of Tracy Bahl and Mike Doherty as independent members of the Board of Directors to provide guidance and support to the continued growth of the business.

“We are very excited to welcome Mike and Tracy to Glooko,” says Russ Johannesson, CEO at Glooko. “We are proud of our distinguished and active board of directors and Tracy and Mike will complement them with their extensive experience. From the start, Glooko has been dedicated to making the lives of people with diabetes easier, and I am convinced that the addition of our new members will add tremendous value supporting our rapid growth in telehealth and clinical research, in both existing and new geographies.”

Bahl, with an extensive background in senior leadership roles at healthcare companies such as CVS Health and UnitedHealth Group, brings expertise in health plan growth and operations, revenue cycle management and healthcare services. As Glooko expands its global provider footprint and partners with payers and employers, Bahl will be tapped for his expertise and guidance.

“I’m thrilled about the opportunity to join Glooko as a board member and be part of this exciting journey”, Bahl said. “This company provides a unique value proposition for patients, providers and payers, and I see a huge potential for Glooko’s services in support of remote care and remote patient monitoring. With the COVID-19 pandemic, which has affected us all, we’ve seen the need and value of telehealth has grown immensely. As we head into the new normal, Glooko can really make a difference by enabling collaboration and remote care in healthcare.”

Doherty joins Glooko’s board with an in-depth knowledge and experience in regulatory affairs, pharmaceutical development, data strategy and clinical research, from a distinguished career in global companies such as AstraZeneca, Roche and Foundation Medicine where he held a variety of senior leadership roles. With Glooko’s focus on enabling virtual clinical studies and global expansion into new markets, Doherty’s experience is particularly valuable.

“I am excited to be part of Glooko’s board of directors”, Doherty said. “I see a great potential for Glooko to add value in the field of clinical research and real world data by enabling clinical trials globally. I look forward to contributing to the global expansion of this exciting company as it transitions into its next phase of growth.”

ABOUT GLOOKO

Glooko is transforming digital health by connecting people with diabetes and their health care professionals, enabling telehealth, clinical research, and improved collaboration.

The company’s software platforms, Glooko® and diasend®, empower diabetes management by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, pens, and activity trackers – bringing insights together in one place.

Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with the vast majority of diabetes devices available, giving people with diabetes and their care teams the freedom of choice.

2.8 million users have benefited from diabetes data insights using Glooko’s solutions, which are trusted by world leaders in diabetes care, and used in 26 countries across 15 languages. Learn more at glooko.com.

MOUNTAIN VIEW, Calif, July 9, 2020 – Together, with Sanofi’s nearly 100-year heritage in diabetes and Glooko’s leadership in remotely connecting people living with diabetes and health care professionals, the companies will collaborate to provide people with diabetes with a digital health solution* to help manage their disease under the virtual guidance of their care teams.

The Glooko Remote Care Solution enables people with diabetes to upload and share data from their diabetes devices with their care providers, who can remotely review diabetes data on the Glooko software platform. Healthcare providers can then provide medical guidance to the person with diabetes via phone, text, or email, bypassing the need for a clinic visit. It is currently being provided free of charge, as a public service to broaden access to telehealth and remote diabetes care during the COVID-19 pandemic.

“At the onset of the pandemic, we quickly realized that we were in a unique position to make a significant contribution towards keeping the diabetes community safe by enabling telehealth and free remote care,” says Russ Johannesson, CEO at Glooko. “We are thrilled to join forces with Sanofi, who share our focus on improving the lives of people with diabetes. Their extensive experience and broad network will support making remote care accessible for even more clinics and people with diabetes.”

“While the world continues to face many challenges as a result of the pandemic, Sanofi is excited to share the Glooko Remote Care Solution with healthcare providers focused on managing diabetes and their patients,” says Chris Boulton, Head of US Diabetes Marketing at Sanofi. “This collaboration puts patient care at the forefront, especially during this stressful time where there is a need for more seamless virtual care.”

To learn more and sign up for Glooko Free Remote Care, visit glooko.com

*Sanofi is not contributing to nor subsidizing the free offer.

ABOUT GLOOKO
Glooko is transforming digital health by connecting people with diabetes and their health care professionals, enabling telehealth, clinical research, and improved collaboration.

The company’s software platforms, Glooko® and diasend®, empower diabetes management by collecting and unlocking the power of data from blood-glucose meters, CGMs, insulin pumps, pens, and activity trackers – bringing insights together in one place.

Data is easily uploaded – remotely via app or in-clinic, securely shared, and visualized in actionable charts and graphs. This creates a solid foundation enabling collaboration and confident treatment decisions. The platforms are compatible with the vast majority of diabetes devices available, giving people with diabetes and their care teams the freedom of choice.

2.8 million users have benefited from diabetes data insights using Glooko’s solutions, which are trusted by world leaders in diabetes care, and used in 26 countries across 15 languages. Learn more at glooko.com.

Transformative Healthcare Technology Entrepreneur joins leader in diabetes data management

MOUNTAIN VIEW, Calif., April 9, 2020 — As part of its continued focus on delivering data enabled solutions to improve the lives of people with diabetes, Glooko, the leader in diabetes digital health, data management solutions and remote monitoring solutions, today announced the appointment of Kyle Brown as Chief Technology Officer.

Brown joins Glooko with an extensive executive background in digital health, where he has successfully built several technology companies focused on the shift from clinician-entered proprietary registries to open and inclusive Patient Insight Networks.

“We’re very excited to have Kyle joining our company at this important time in our development. His extensive experience building data-driven healthcare technology businesses, together with his unique background in software development, patient advocacy, and support of clinical research, will be incredibly valuable for Glooko as we continue to grow” said Russ Johannesson, CEO of Glooko.

In his new role with Glooko, Brown will have global responsibility for all technology and engineering efforts
“Glooko’s work enhancing the patient-clinician relationship, especially in these times of accelerating adoption of remote care and telemedicine technologies, is a perfect match with my passion for leveraging the digital content to improve patient care,” Brown said. “I am very excited to be a part of the company’s global expansion to create new ways to better engage people with diabetes”.
Brown comes to Glooko from PatientCrossroads/AltaVoice, which he founded and led for over a decade. The company’s mission was to harness the collective knowledge of patient communities to drive faster treatments while creating a market for patient provided data. As CEO, Brown led the implementation of over 125 patient registry programs collecting data on more than 400 diseases in collaboration with advocacy, academia, government and pharmaceutical companies.

About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.8 million people with diabetes and are used in 9,000+ clinic locations in 25 countries across 15 languages. Learn more by visiting www.glooko.com

Media Contacts
For inquiries, please email [email protected].

STATEMENT FROM GLOOKO RE: COVID-19 SERVICE

MOUNTAIN VIEW, Calif., March 19, 2020 — Throughout this challenging time of the COVID-19 pandemic, Glooko, a leading diabetes software company that enables people with diabetes and clinicians to manage care in real-time, is committed to helping ensure the health and well-being of people with diabetes, their caregivers, and their healthcare professionals. Glooko is therefore taking action to serve the global diabetes community by providing a no-charge remote-care solution that provides live patient-to-clinician connectivity.

As many efforts undertaken in our communities are aimed at reducing the chances of being exposed to and spreading COVID-19, that individuals who have chronic conditions like diabetes and contract the virus appear to be at a higher risk for developing complications; as such limiting exposure is critical. For certain appointments, healthcare professionals may determine that the patient and their care team would be best served by a remote review of the patient’s personal diabetes data and a corresponding telehealth consult, reserving in-office visits only for those appointments where a patient’s medical status truly requires in-person treatment.

To minimize the risk to people with diabetes during this time by broadening access to remote medical appointments with healthcare providers, Glooko is offering its secure, privacy-protected remote-care solution at no charge to medical clinics and people with diabetes as a public service until the greatest threat of the pandemic has subsided.

This public service is being made available to medical clinics and people with diabetes in countries where Glooko technology is already provided. Interested medical clinics and people with diabetes can learn more about how to access the Glooko remote-care solution at www.glooko.com.

About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® by Glooko diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.8 million people with diabetes and are used in 9,000+ clinic locations in 25 countries across 15 languages. Learn more by visiting www.glooko.com

Media Contacts
For inquiries, please email [email protected].

Accomplished business and operational leaders join leader in diabetes data management

MOUNTAIN VIEW, Calif., February 13, 2020 — As part of its continued global expansion, Glooko, the leader in diabetes digital health and data management solutions, today announced the appointment of Zach Henderson as Chief Commercial Officer and Komathi Stem as Chief Operating Officer. Henderson joins Glooko with extensive executive background at healthcare data and analytics companies leading a range of commercial functions, from alliance management and portfolio strategy to sales, marketing, and revenue generation. Stem comes to Glooko having served in a wide range of leadership roles in the life science industry with a focus on the use of real-world data and digital technologies to transform and accelerate clinical trials.

“We’re pleased to have Komathi and Zach joining us now as we expand our offerings to help the global healthcare ecosystem better understand and manage diabetes and support health care providers managing their patient populations using our data, analytics, and clinical research solutions,” said Russ Johannesson, CEO of Glooko. “The year ahead holds tremendous potential for Glooko and having the depth of business and leadership experience that Zach and Komathi bring will be a major advantage as we look forward to significantly increasing our positive impact in the diabetes community.”

In his new role with Glooko, Henderson will have global responsibility for all commercial efforts, including the company’s work with its key strategic partners and revenue generation initiatives.

“As the leader in diabetes data management, Glooko is integrated with more diabetes and health devices than any other platform in the world, creating an opportunity to provide extensive insights. We have a unique opportunity to improve the lives of those with diabetes by leveraging the global Glooko data platform to advance research and the treatment of patients,” said Henderson. “I’m excited to be joining the Glooko team as it transitions to its next phase of growth.”

Henderson comes to Glooko from LexisNexis Health Care and Elsevier, where he served as vice president of strategy, alliances and data sourcing and was responsible for the creation and development of a strategic alliance program of go-to-market and enablement partners, the negotiation of strategic partnership deals, and the integration of new business acquisitions. Prior to LexisNexis, he served in a range of senior commercial leadership roles at healthcare data and analytics companies, including Health Market Science and IMS Health (now IQVIA). Henderson earned an MBA from Villanova University.

In her new role as COO of Glooko, Stem will have global responsibility for Glooko product development, clinical research, and customer support.

In her previous role, Stem was founder and CEO of monARC Bionetworks, a health data collection and analytics company aimed at modernizing clinical research by empowering patients to share their real-world data generated from routine care and digital tools so it can be transformed into real-world evidence that accelerates research and improves care.

“Glooko’s mission to empower people with diabetes to use their data to improve care and contribute real-world data to advance research is completely aligned with my passion to transform research and care using the growing body of real-world data,” Stem said. “I’m pleased to be joining the Glooko team as we continue leading the way in turning integrated diabetes data into actionable insights for people with diabetes and their providers.”

Prior to monARC Bionetworks, Stem has led the transformation of clinical trials via her leadership roles at Science 37, Genentech, AstraZeneca, Amgen and Eli Lilly. She holds a Master of Science degree in biomedical engineering from the University of Virginia.

About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 24 countries across 15 languages. Learn more by visiting www.glooko.com

Media Contacts

Robin Beadle
Glooko
[email protected]

Jeff Christensen
SignalWest Public Relations
+1 831-566-0275
[email protected]

Recognition of a Significant Milestone in Larger Data Protection Program of Diabetes Data Management Pioneer
MOUNTAIN VIEW, Calif., Dec. 11, 2019 /PRNewswire/ — Glooko®, the global leader in diabetes data management, today announced it has received Privacy Shield certification from the U.S. Department of Commerce. This official recognition verifies the company has taken specific steps to ensure the protection of consumers’ personal data when transferring it from Europe to the U.S. and has committed to the Privacy Shield Principles, which are intended to protect against the misuse and unwarranted collection of personally-identifying patient information.

In an era of well-publicized consumer data breaches, data privacy and security is a major concern for internet users and has become a growing problem across the board in business. The healthcare industry, in fact, has become particularly susceptible to cyberattacks, and at an average cost of $6.45 million per breach of patient data, health care has the highest average cost per breach of all U.S. business sectors, according to this year’s “Cost of a Data Breach Report” from IBM and the Ponemon Institute. Recent U.S. healthcare data breaches have been attributed to a range of causes, including hacking, IT incidents, and theft, loss, improper disposal, and unauthorized access or disclosure of patient records.

To add to it, the number of breaches in health care continues to increase. After reaching a record high once in 2018 and twice more early this year for the number of data breaches in a single month, U.S. healthcare organizations reached an all-time high yet again in July, reporting a total of 50 data breaches, the most reported in a single month since the HHS Office for Civil Rights established its online database of healthcare breaches in 2010.

That’s why Glooko is especially pleased to have the chance to help lead the way in Privacy Shield certification for diabetes device and data management companies, as only about 10 percent of such companies have pursued and achieved the certification to date.i Even still, the company believes certification must be about more than compliance.

“We’re grateful for Privacy Shield certification and that the mechanism is there to help with compliance. Nevertheless, Glooko has set an internal standard that goes beyond just meeting the minimum requirements regarding data laws,” said Russ Johannesson, CEO of Glooko. “Managing diabetes requires gathering and handling a lot of personal data, and because we believe people with diabetes own their data and protecting their privacy comes first, earning their trust and that of their healthcare providers is our real objective. That far surpasses simply staying inside the lines.”

Privacy Shield was created by the Commerce Department, the European Commission, and the Swiss Administration, and it was activated in 2016. To earn certification, a U.S. company is required to conduct a self-certification process for the Commerce Department and publicly commit to comply with the Privacy Shield Principles. And while Privacy Shield certification is voluntary for U.S. companies, once an eligible company commits to comply with the requirements, the commitment becomes enforceable under U.S. law.

Glooko is proud to have earned the Privacy Shield certification, but it’s a milestone that supports just one part of the larger three-part data protection program that the company is implementing and has made a focus of how it operates. First, Glooko has made a formal declaration of its values regarding data ethics and patient rights via the development and adoption of its Data Ethics Policy, which serves as a guiding light for how the company and its employees will handle health data. It has also gone to great lengths to author and establish its data privacy policies, formalizing them through official certifications like Privacy Shield. And the most rigorous part of Glooko’s program is its actual safeguarding of the data managed on its platform through installing strong security controls, a demanding process being validated by Glooko’s pursuit of the industry-driven seal of approval known as HITRUST Certification.

“As people with diabetes and clinics are managing billions of data points on the Glooko platform, we’re at ‘center stage’ in today’s digital diabetes landscape,” said Melissa Liu, Glooko’s Senior Director of Operations, Privacy & Security. “In light of that pivotal role in handling so much sensitive data, our uncompromising efforts should reassure anyone working with us that Glooko is trustworthy and committed to data protection, from patients and providers to healthcare systems and the device companies with whom we partner.”

About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 24 countries across 15 languages. Learn more by visiting www.glooko.com

Media Contacts:

Holly McGarraugh

Glooko

510-282-2852

Jeff Christensen

SignalWest Public Relations

+1 831-566-0275

[email protected]

Milestone verifies digital health leader’s commitment to ensuring quality and safety of its products

MOUNTAIN VIEW, Calif., Dec. 10, 2019 /PRNewswire/ — Glooko®, the global leader in diabetes data management, announced today that its Mountain View, California and Gothenburg, Sweden sites have received joint ISO 13485:2016 certification from accredited certification body Intertek Testing Services NA Ltd. This certification demonstrates Glooko’s commitment to establishing a compliant quality management system and following practices and procedures that meet customer, safety and regulatory requirements applicable to medical devices. It verifies for regulators, strategic partners, and the diabetes community that Glooko is committed to ensuring the quality and safety of its digital health products and services.

ISO 13485 is an International Organization for Standardization (ISO) standard that describes the requirements for comprehensive practices and procedures for the design, development, production, and delivery of medical devices, including digital health software. To become ISO 13485 certified, Glooko underwent thorough evaluations of its corporate quality management system via a Stage 1 pre-certification audit in June 2019 and Stage 2 certification audits in September 2019 (Mountain View) and October 2019 (Gothenburg), with zero Stage 2 nonconformities noted.

“Organizations in the medical device industry are required to demonstrate their quality management processes and ensure they’re following regulations and standards for developing safe and reliable products,” said Russ Johannesson, CEO of Glooko. “Our certification to ISO 13485 is an important milestone that confirms our quality management system has met internationally-recognized requirements, and that Glooko is committed to ongoing compliance and improvement.”
Because digital health products like Glooko must comply with regulatory standards that meet the quality, safety and clinical needs of people with diabetes and their providers, quality management in digital health is about more than simply developing and testing software.

“Being certified to the ISO 13485 standard is especially important because digital health software is more than a tech product—it is a healthcare product with global quality and safety requirements,” said Mary Beth McDonald, senior director of regulatory and quality management for Glooko.

Beyond regulatory compliance, ISO 13485 certification demonstrates the robustness of Glooko’s quality management system to the Food and Drug Administration (FDA), European Union, and Glooko’s strategic partners.

About Glooko
Glooko’s universal diabetes software products provide insights to improve outcomes for people with diabetes and their care teams. The Glooko product suite contains the Glooko and diasend® diabetes management solutions, which integrate with many of the leading EHR systems used today. Both systems synchronize data from more than 190 diabetes devices and activity trackers, and they deliver integrated, timely and useful patient data, including glucose levels, blood pressure, weight, and food, insulin and medication intake. Trusted by the world’s leaders in diabetes care, our solutions cover more than 2.2 million people with diabetes and are used in 9,000+ clinic locations in 24 countries across 15 languages. Learn more by visiting www.glooko.com

Media Contacts:
Holly McGarraugh
Glooko
510-282-2852

Jeff Christensen
SignalWest Public Relations
+1 831-566-0275
[email protected]